Журнал рецептурной науки и биодоступности

Features of Biopharmaceutics to Address the Bio Waiver of Immediate and Longer Release Tablets

Abstract

Alesya Rania*

Pharmacokinetic profile and few adverse effects, gliclazide is listed as an important medication by the World Health Organization and Brazil as an alternative to metformin, the oral antidiabetic agent of first preference for the treatment of type diabetes mellitus. Due to this, it is also taken into account by and the International Pharmaceutical Federation as a drug candidate for, which is an assessment of how favourable the biopharmaceutics characteristics are in order to obtain waiver from the relative bioavailability/bioequivalence studies in order to register new medicines. This essay provides a review of solubility, permeability, and dissolution. A rigorous study of the evidence enabled to identify gliclazide as a Biopharmaceutics Classification System Class medication.